Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe

Author： Zanger P.   Kötter I.   Kremsner P. G.   Gabrysch S.  

Publisher： Blackwell Publishing

ISSN： 1198-743X

Source： Clinical Microbiology & Infection, Vol.18, Iss.7, 2012-07, pp. : 670-676

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Structural biology of tumor necrosis factor demonstrated for undergraduates instruction by computer simulation

By  

Biochemistry and Molecular Biology Education, Vol. 44, Iss. 3, 2016-05 ,pp. : 246-255

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drugs

By Cereijo Ines  

Journal of AOAC International, Vol. 87, Iss. 1, 2004-01 ,pp. : 259-261

AOAC International

Access to resources Recommend Favorite

Leishmaniasis in immunosuppressed individuals

By Griensven J.   Carrillo E.   López-Vélez R.   Lynen L.   Moreno J.  

Clinical Microbiology & Infection, Vol. 20, Iss. 4, 2014-04 ,pp. : 286-299

Blackwell Publishing

Access to resources Recommend Favorite

Leishmaniasis chemotherapy—challenges and opportunities

By Croft S. L.   Olliaro P.  

Clinical Microbiology & Infection, Vol. 17, Iss. 10, 2011-10 ,pp. : 1478-1483

Blackwell Publishing

Access to resources Recommend Favorite

Leishmaniasis impact and treatment access

By den Boer M.   Argaw D.   Jannin J.   Alvar J.  

Clinical Microbiology & Infection, Vol. 17, Iss. 10, 2011-10 ,pp. : 1471-1477

Blackwell Publishing

Access to resources Recommend Favorite